Levi & Korsinsky, LLP: Institutional Investor Notice --- Ultragenyx Pharmaceutical Lead Plaintiff Opportunity

Notice to Pension Funds, Asset Managers, and Fiduciaries

NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between August 3, 2023 and December 26, 2025. The window to apply for lead plaintiff closes on April 6, 2026.

Request information for institutional investors

You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.

Notice to Institutional Holders

Institutional investors holding positions in Ultragenyx during the Class Period may wish to evaluate lead plaintiff opportunities and portfolio recovery options. The securities action alleges that management made materially false and misleading statements regarding the Company's Phase III clinical studies for setrusumab in osteogenesis imperfecta.

ERISA and Fiduciary Considerations

Fiduciaries have obligations to monitor investments and evaluate recovery opportunities. As claimed, the alleged misrepresentations may have caused significant portfolio losses for institutional holders who relied on management's repeated confidence statements about clinical trial outcomes.

Fiduciary Obligations and Recovery Options

Institutional investors with substantial losses may be well-positioned to serve as lead plaintiff and direct the litigation
Lead plaintiff selection criteria favor shareholders with the largest financial interest in the recovery
Fiduciaries may have obligations to evaluate participation in securities class actions affecting portfolio holdings
No out-of-pocket costs are required for class members; attorneys' fees are paid from any recovery
Our firm has extensive experience representing pension funds, mutual funds, and asset managers in complex securities litigation

Case Summary

The securities action, filed in the United States District Court, Northern District of California, alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act. As claimed, the Company and certain officers made false and misleading statements about the Phase III Orbit and Cosmic clinical studies, causing investors to purchase shares at artificially inflated prices.

"Institutional investors play a critical role in securities class actions, and our firm has extensive experience representing pension funds and asset managers," said Joseph E. Levi, Esq.

INSTITUTIONAL INVESTOR REPRESENTATION

Levi & Korsinsky, LLP provides sophisticated counsel to institutional investors evaluating lead plaintiff opportunities and securities class action participation. The firm has recovered hundreds of millions of dollars for institutional and individual investors. Ranked among ISS Securities Class Action Services' Top 50 for seven consecutive years.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
(212) 363-7500
jlevi@levikorsinsky.com
www.zlk.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.